Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Engineering cord blood to improve engraftment after cord blood transplant.

Mehta RS, Dave H, Bollard CM, Shpall EJ.

Stem Cell Investig. 2017 May 25;4:41. doi: 10.21037/sci.2017.05.01. eCollection 2017. Review.

2.

Progress in Treatment of Viral Infections in Children with Acute Lymphoblastic Leukemia.

Moschovi M, Adamaki M, Vlahopoulos SA.

Oncol Rev. 2016 Jun 30;10(1):300. doi: 10.4081/oncol.2016.300. eCollection 2016 Apr 15. Review.

3.

Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes.

Naik S, Nicholas SK, Martinez CA, Leen AM, Hanley PJ, Gottschalk SM, Rooney CM, Hanson IC, Krance RA, Shpall EJ, Cruz CR, Amrolia P, Lucchini G, Bunin N, Heimall J, Klein OR, Gennery AR, Slatter MA, Vickers MA, Orange JS, Heslop HE, Bollard CM, Keller MD.

J Allergy Clin Immunol. 2016 May;137(5):1498-1505.e1. doi: 10.1016/j.jaci.2015.12.1311. Epub 2016 Feb 24.

4.

Functionally Active HIV-Specific T Cells that Target Gag and Nef Can Be Expanded from Virus-Naïve Donors and Target a Range of Viral Epitopes: Implications for a Cure Strategy after Allogeneic Hematopoietic Stem Cell Transplantation.

Patel S, Lam S, Cruz CR, Wright K, Cochran C, Ambinder RF, Bollard CM.

Biol Blood Marrow Transplant. 2016 Mar;22(3):536-41. doi: 10.1016/j.bbmt.2015.12.007. Epub 2015 Dec 22.

5.

Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances.

McLaughlin L, Cruz CR, Bollard CM.

Ther Adv Hematol. 2015 Dec;6(6):295-307. doi: 10.1177/2040620715594736. Review.

6.
7.

Lymphoma Immunotherapy: Current Status.

Zappasodi R, de Braud F, Di Nicola M.

Front Immunol. 2015 Sep 1;6:448. doi: 10.3389/fimmu.2015.00448. eCollection 2015. Review.

8.
9.

K562-Derived Whole-Cell Vaccine Enhances Antitumor Responses of CAR-Redirected Virus-Specific Cytotoxic T Lymphocytes In Vivo.

Caruana I, Weber G, Ballard BC, Wood MS, Savoldo B, Dotti G.

Clin Cancer Res. 2015 Jul 1;21(13):2952-62. doi: 10.1158/1078-0432.CCR-14-2998. Epub 2015 Feb 17.

10.

Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord blood.

Hanley PJ, Bollard CM, Brunstein CG.

Cytotherapy. 2015 Jun;17(6):749-755. doi: 10.1016/j.jcyt.2014.12.007. Epub 2015 Jan 24. Review.

11.

IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia.

Pegram HJ, Purdon TJ, van Leeuwen DG, Curran KJ, Giralt SA, Barker JN, Brentjens RJ.

Leukemia. 2015 Feb;29(2):415-22. doi: 10.1038/leu.2014.215. Epub 2014 Jul 9.

12.

Antibody-modified T cells: CARs take the front seat for hematologic malignancies.

Maus MV, Grupp SA, Porter DL, June CH.

Blood. 2014 Apr 24;123(17):2625-35. doi: 10.1182/blood-2013-11-492231. Epub 2014 Feb 27. Review.

13.

Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition.

Perna SK, Pagliara D, Mahendravada A, Liu H, Brenner MK, Savoldo B, Dotti G.

Clin Cancer Res. 2014 Jan 1;20(1):131-9. doi: 10.1158/1078-0432.CCR-13-1016. Epub 2013 Oct 4. Erratum in: Clin Cancer Res. 2014 Aug 15;20(16):4413.

14.

Chimeric antigen receptors (CARs) from bench-to-bedside.

Savoldo B, Dotti G.

Immunol Lett. 2013 Sep-Oct;155(1-2):40-2. doi: 10.1016/j.imlet.2013.09.014. Epub 2013 Sep 27. Review.

15.

Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.

Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, Diouf O, Liu E, Barrett AJ, Ito S, Shpall EJ, Krance RA, Kamble RT, Carrum G, Hosing CM, Gee AP, Mei Z, Grilley BJ, Heslop HE, Rooney CM, Brenner MK, Bollard CM, Dotti G.

Blood. 2013 Oct 24;122(17):2965-73. doi: 10.1182/blood-2013-06-506741. Epub 2013 Sep 12. Erratum in: Blood. 2014 May 22;123(21):3364.

16.

Antiviral cell therapy: is this the future?

Gea-Banacloche JC.

Blood. 2013 Jun 27;121(26):5108-9. doi: 10.1182/blood-2013-05-500082. No abstract available.

17.

Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies.

Warren EH, Deeg HJ.

Tissue Antigens. 2013 Apr;81(4):183-93. doi: 10.1111/tan.12090. Review.

18.

Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells.

Maher J.

ISRN Oncol. 2012;2012:278093. doi: 10.5402/2012/278093. Epub 2012 Dec 9.

19.

Cord blood graft engineering.

Delaney C, Bollard CM, Shpall EJ.

Biol Blood Marrow Transplant. 2013 Jan;19(1 Suppl):S74-8. doi: 10.1016/j.bbmt.2012.10.015. Epub 2012 Oct 17. Review. No abstract available.

20.

Genetic modification of human T lymphocytes for the treatment of hematologic malignancies.

Hoyos V, Savoldo B, Dotti G.

Haematologica. 2012 Nov;97(11):1622-31. doi: 10.3324/haematol.2012.064303. Epub 2012 Aug 28. Review.

Supplemental Content

Support Center